ClinicalTrials.gg
Not yet recruitingNCT07519499Updated Apr 9, 2026

Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection

A Phase 2 interventional study of XKH001Injection and Placebo in COPD, sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD. Not yet recruiting. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-parallel-controlled, two-stage design, Phase II clinical study. This study is divided into two stages. Stage 1 (Phase IIa) has a dosing duration of 24 weeks (treatment period of 28 weeks) and aims to preliminarily evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD. Stage 2 (Phase IIb) has a dosing duration of 48 weeks (treatment period of 52 weeks) and aims to further evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-parallel-controlled, two-stage design, Phase II clinical study. This study is divided into two stages. Stage 1 (Phase IIa) has a dosing duration of 24 weeks (treatment period of 28 weeks) and aims to preliminarily evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD. Stage 2 (Phase IIb) has a dosing duration of 48 weeks (treatment period of 52 weeks) and aims to further evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD.

Stage 1 (Phase IIa) All trial participants who have signed the ICF will enter the Screening Period and undergo corresponding screening investigations. The screening period is a maximum of 28 days.

Eligible trial participants from screening (a total of 75 participants, including 45 with a whole blood EOS count ≥300/μL and 30 with an EOS count \<300/μL) will enter the 28-week Treatment Period (dosing with investigational drug or placebo once every 4 weeks for a total of 7 doses), and their eligibility for enrollment will be reconfirmed before randomization. On Day 1, participants will be randomized in a 1:1:1 ratio to two dose groups of the investigational drug XKH001 Injection (300 mg once every four weeks [Q4W] or 600 mg Q4W) or placebo group, with 25 participants in each group, stratified by whole-blood EOS count (≥300/μL vs. \<300/μL) during the screening. During the treatment period, trial participants will undergo corresponding efficacy and safety assessments at specified time points (including before each dose administration). Sampling for laboratory tests must be completed before administration.

COPD trial participants who complete the 28-week treatment period will enter an 8-week Follow-up Period and will return to the hospital every 4 weeks (at Weeks 32 and 36) for corresponding safety and efficacy assessments.

During the study, trial participants will also have biological samples collected for PK, immunogenicity, and exploratory biomarker analysis at specified time points (including before each dose administration).

All trial participants should be on stable inhaled maintenance background therapy for COPD for at least 1 month before signing the ICF, during the screening period, and until the end of the study. From the time of signing the ICF until study completion or withdrawal from the study, trial participants must record their use of background therapy in a diary card. Throughout the study, trial participants may use drugs such as Salbutamol/Levalbuterol as needed for symptom relief. Participants must record the time, reason, dosage, and frequency of use in detail in their daily diary card.

Stage 2 (Phase IIb) All trial participants who have signed the ICF will enter the Screening Period and undergo corresponding screening investigations. The screening period is a maximum of 28 days.

Eligible trial participants from screening will enter the 52-week Treatment Period (dosing with investigational drug or placebo Q4W for a total of 13 doses), and their eligibility for enrollment will be reconfirmed before randomization. On D1, trial participants will be randomized in a 1:1:1:1 ratio to 3 dose groups of the investigational drug XKH001 Injection (100 mg Q4W, 300 mg Q4W, 600 mg Q4W) or the placebo group, stratified by whole blood EOS count during the screening period (≥300/μL vs. \<300/μL) (tentative). During the treatment period, trial participants will undergo corresponding efficacy and safety assessments at specified time points (including before each dose administration). Sampling for laboratory tests must be completed before administration.

Note: The randomization stratification factor for Stage 2 (Phase IIb) and the sample size estimation for Stage 2 (Phase IIb) will be adjusted based on the results of Stage 1 (Phase IIa).

COPD trial participants who complete the 52-week treatment period will enter a 12-week Follow-up Period and will return to the hospital every 4 weeks (at Weeks 56, 60, and 64) for corresponding safety and efficacy assessments.

During the study, trial participants will also have biological samples collected for PK, immunogenicity, and exploratory biomarker analysis at specified time points (including before each dose administration).

All trial participants should be on stable inhaled maintenance background therapy for COPD for at least 1 month before signing the ICF, during the screening period, and until the end of the study. From the time of signing the ICF until study completion or withdrawal from the study, trial participants must record their use of background therapy in a diary card. Throughout the study, trial participants may use drugs such as Salbutamol/Levalbuterol as needed for symptom relief. Participants must record the time, reason, dosage, and frequency of use in detail in their daily diary card.

02

Conditions studied

03

In context

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

This study's planned enrollment of 75 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Zhejiang Kanova Biopharmaceutical Co., LTD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Trial participants must meet all of the following inclusion criteria to be enrolled in this study:

    1. The trial participant is able to understand the procedures and methods of this study, is willing to sign the ICF and strictly adhere to the clinical study protocol to complete this study, and can independently complete study-related questionnaires;
    2. The trial participant must be aged 40-80 years (inclusive) at the time of signing the ICF, can be either male or female;
    3. The trial participant has a ≥16.0 kg/m2;
    4. Trial participants diagnosed with for ≥12 months (diagnosed according to GOLD 2024) and meeting the following criteria:

      • Current smoker or ex-smoker with a smoking history of ≥10 pack-years (1 pack-year is calculated as: [average number of cigarettes smoked per day × number of years]/20; e.g., 1 pack-year = smoking 20 cigarettes per day for 1 year, or smoking 10 cigarettes per day for 2 years.); Moderate to severe airflow limitation (post-bronchodilator /FVC \<70%, post-bronchodilator FEV1 measurement ≥30% and \<80% of predicted value);
      • Documented high risk of exacerbations, defined as ≥2 moderate or ≥1 severe exacerbations in the year prior to screening: A moderate exacerbation is defined as an AECOPD requiring the use of systemic (intramuscular, intravenous, or oral) and/or antibiotics (however, the use of antibiotics alone does not qualify as a moderate exacerbation unless it is documented that the antibiotic use was necessary to treat worsening COPD symptoms); one of the two required moderate exacerbations must have required systemic corticosteroids; a severe exacerbation is defined as an AECOPD requiring hospitalization or observation in an emergency room/urgent care facility for >24 hours;
      • Received inhaled background maintenance therapy [triple therapy (ICS + LABA + LAMA) or dual therapy (LABA + LAMA or ICS + LABA)] for ≥3 months before randomization, with a stable dose for at least 1 month before signing the ICF and during the screening period;
    5. Whole blood EOS count ≥150/μL during the screening period;
    6. Female trial participants of and their male partners, and male trial participants and their female partners, must agree to use an effective method of during the study and for 6 months after the last dose of drug, and have no plans for childbirth, sperm donation, or ovum donation (see Appendix 1: Contraceptive Measures, Definition of Childbearing Potential, and Contraception Requirements for details).

Exclusion criteria

Exclusion Criteria:

  • Trial participants with any of the following cannot be enrolled in this study:

    1. Presence of any respiratory disorder other than , including:

      • Current diagnosis of asthma or a history of asthma according to the GINA or other recognized guidelines;
      • Diagnosis of alpha-1 antitrypsin deficiency;
      • Other concomitant active or respiratory disorders that would significantly affect the study: such as active pulmonary tuberculosis, lung cancer (including suspected malignant pulmonary nodule [Category 4]), bronchiectasis, sarcoidosis, pulmonary fibrosis, interstitial lung disease, cystic fibrosis, obliterative bronchiolitis, pulmonary arterial hypertension, etc.;
    2. AECOPD (including mild, moderate, and severe; for definitions of moderate and severe AECOPD, see Inclusion Criterion 4, item 3) and/or respiratory tract infection within 4 weeks prior to screening and before randomization;
    3. Signs and/or symptoms of cor pulmonale and/or right ventricular failure;
    4. Hypercapnia requiring the use of BiPAP;
    5. Currently receiving or planning to start long-term oxygen therapy (>15 hours of oxygen per day) or mechanical ventilation during the study;
    6. Participation or planned participation in an intensive COPD rehabilitation program within 4 weeks prior to screening (trial participants in the maintenance phase of a rehabilitation program may be considered for enrollment);
    7. Planned pulmonary resection or lung volume reduction surgery, or a history of such surgery;
    8. Presence of any Grade ≥2 ( version 6.0) lipid profile abnormalities (the influence of physiological factors such as diet should be excluded);
    9. Concomitant disease requiring systemic therapy (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis);
    10. Known or suspected history of an immunosuppressive disease, including a history of invasive opportunistic infections (e.g., TB, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved/subsided; or, in the investigator's judgment, a history of abnormally frequent, recurrent, or prolonged infections;
    11. Confirmed active infection parasitic; suspected infection parasitic or high risk of infection, unless clinical assessment and (if necessary) laboratory assessment have ruled out active infection before randomization;
    12. Confirmed acute or chronic infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitic, or antiprotozoals within 4 weeks prior to screening or during the screening period;
    13. Undergone Grade III or IV surgery (as defined in the "Administrative Measures for the Grading of Medical Institution Surgeries", see Appendix 2: Surgical Grading Management for details) within 12 weeks prior to screening (excluding paracentesis ); or planned surgery requiring general anesthesia or hospitalization >1 day during the study;
    14. Presence of other serious diseases that, in the investigator's judgment, may affect the patient's participation in this trial, including but not limited to: diseases that severely affect survival, uncontrolled diabetes mellitus, renal insufficiency requiring dialysis, Class B/C liver function, demyelination diseases, neurological and psychological disorders, etc.;
    15. Clinically significant cardiovascular disorder within 6 months prior to screening. Cardiovascular disorders include but are not limited to:

      • Two-dimensional echocardiogram showing an \<50%;
      • Acute myocardial infarction;
      • Severe/unstable angina;
      • History of arterial thromboembolism, including but not limited to cerebrovascular accident and ;
      • Cardiac failure congestive ( functional class >II);
      • Any clinically significant abnormality in rhythm, conduction, or morphology on a resting , complete bundle branch block left, third-degree heart block, second-degree heart block, PR interval >250 msec;
      • Mean resting ≥500 msec obtained from 3 ECGs (corrected using Fridericia's formula, see Appendix 3: Calculation Formulas for QTcF and RR for details);
      • Any factor that increases the risk of QTc interval prolongation or arrhythmic events, such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death in a first-degree relative under 40 years of age, or any concomitant medication known to prolong the QT interval;
      • Hypertension not controlled by antihypertensive medication (blood pressure systolic >160 mmHg and/or blood pressure diastolic >100 mmHg);
    16. Trial participants with a neoplasm malignant within 5 years prior to screening or currently (Note: ① Trial participants with carcinoma in situ of the cervix that has been resected, adequately treated, and currently has no evidence of disease recurrence may participate in this study; ② Trial participants with basal cell carcinoma or squamous cell carcinoma of the skin that has been completely resected, adequately treated, and currently has no evidence of disease recurrence may participate in this study);
    17. Patients receiving the following drugs or treatments that are prohibited as concomitant therapy:

      • Prior use of biologics with efficacy in treating COPD, such as Benralizumab, Mepolizumab, Omalizumab, Dupilumab, etc. (for Phase IIb, enrollment may be considered based on use and therapeutic effect, as assessed by the investigator);
      • Received aminophylline, PDE-4 inhibitors, leukotriene receptor antagonists, and other systemic treatments for COPD within 2 weeks or 5 t1/2 (whichever is longer) before the first dose;
      • Received systemic (excluding topical, ophthalmic, or intranasal use of corticosteroids) or systemic immunosuppressants/immunomodulators (e.g., Methotrexate) within 4 weeks before the first dose;
      • Use of Chinese herbal medicines with therapeutic effects on COPD (excluding topical preparations) within 4 weeks before the first dose;
      • Received IVIG therapy or allergen-SIT within 8 weeks or 5 t1/2 (whichever is longer) before the first dose;
      • Received B- and/or T-cell targeted immunosuppressive therapy within 8 weeks or 5 t1/2 (whichever is longer) before the first dose;
      • Planned vaccination with a live or within 12 weeks before the first dose or during the study;
      • Received other biologics such as anti-TNF monoclonal antibody therapy within 16 weeks or 5 t1/2 (whichever is longer) before the first dose;
      • Received macrolide antibiotic therapy within 6 weeks prior to screening (except for those who had been on a stable dose of macrolide antibiotics for ≥6 months prior to screening and had at least 1 AECOPD during this period).
    18. Received blood products such as human blood albumin, hematopoietic growth factors (e.g., G-CSF), or -increasing therapy within 2 weeks prior to screening;
    19. Any of the following abnormalities in laboratory test results at screening:

      • ANC \<1.5 × 109/L;
      • >1.5 × ;
      • or ALT >2 × ULN;
      • \<50 mL/min (calculated by the Cockcroft-Gault formula);
      • PLT \<90 × 109/L;
      • HGB \<90 g/L;
      • Other clinically significant laboratory test abnormalities that, in the investigator's judgment, make the participant unsuitable for enrollment; Note: If a laboratory test result exceeds the protocol-specified threshold but is suspected to be transient (due to physiological factors, test error, etc.), or is only slightly above the threshold, it may be re-tested once (and only once) during the screening period for clarification. If the re-test result still exceeds the threshold, the trial participant will be a screen failure;
    20. Presence of any of the following infectious diseases:

      • Positive for , or negative for HBsAg but positive for HBcAb and positive for HBV-DNA; positive for -Ab and positive for HCV-RNA;
      • Positive for TP-Ab (unless negative on RPR or TRUST);
      • Positive for antibody;
    21. History of severe allergic reaction or known allergy to XKH001 Injection or its ;
    22. History of fainting at the sight of blood or from needles;
    23. Pregnant or lactating females;
    24. Blood donation or blood loss of ≥400 mL within 12 weeks prior to screening, or received a transfusion within 4 weeks prior to screening;
    25. Participation in any other clinical study (including drug and device studies) and use of an drug or medical device intervention within 12 weeks or 5 t1/2 (whichever is longer) prior to screening (calculated from the time of the last use of the investigational drug or medical device intervention);
    26. History of alcohol abuse or various drug abuse within 2 years prior to signing the ICF;
    27. Other factors that, in the investigator's opinion, make the participant unsuitable for the study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    XKH001 300mg

    XKH001 Injection 300 mg once every four weeks \[Q4W\]

    Drug: XKH001Injection · Drug: Placebo

  • Active comparator
    XKH001 600mg

    XKH001 Injection 600 mg once every four weeks \[Q4W\]

    Drug: XKH001Injection

  • Placebo comparator
    Placebo group

    Placebo once every four weeks \[Q4W\]

    Drug: Placebo

Interventions

  • XKH001, developed by Zhejiang Kanova Biopharmaceutical Co., Ltd., is a recombinant anti-IL-25 humanized IgG1 monoclonal antibody (mAb) composed of two identical light chains and two identical heavy chains linked by disulfide bonds. Each light chain consists of 215 amino acids, and each heavy chain consists of 455 amino acids, for a total of 1340 amino acids. XKH001 has a total of 16 pairs of disulfide bonds, including 4 pairs of intra-light chain disulfide bonds, 8 pairs of intra-heavy chain disulfide bonds, 2 pairs of light-heavy interchain disulfide bonds, and 2 pairs of heavy-heavy interchain disulfide bonds. XKH001 has an N-glycosylation site at N305 of the heavy chain, with G0F oligosaccharide being the major form of N-glycosylation.

    Also known as: XKH001

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Primary Outcome1

    Causal relationship to the investigational product of TEAEs

    Time frame: Week 36

  2. Primary Outcome2

    Change from baseline in post-bronchodilator FEV1 (mL) at Week 28

    Time frame: Week 28

Secondary outcomes

  1. Secondary Outcome1

    Change from baseline in post-bronchodilator FEV1 (mL) at Weeks 2, 4, 8, 12, 16, 20, 24, and 32;

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, and 32;

  2. Secondary Outcome2

    Percentage change from baseline in post-bronchodilator FEV1 (%) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  3. Secondary Outcome3

    Change and percentage change from baseline in pre-bronchodilator FEV1 (mL and %) at Week 28;

    Time frame: Week 28

  4. Secondary Outcome4

    Change and percentage change from baseline in FEF 25%-75% (L/s and %) at Week 28;

    Time frame: Week 28

  5. Secondary Outcome5

    Change from baseline in SGRQ(St. George's Respiratory Questionnaire,Very good (1) □Good (2) □Average (3) □Poor (4) □Very poor (5)) total score at Weeks 4, 8, 12, 16, 20, 24, 28, and 32;

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  6. Secondary Outcome6

    Proportion of trial participants with an improvement of ≥4 points in SGRQ(St. George's Respiratory Questionnaire,Very good (1) □Good (2) □Average (3) □Poor (4) □Very poor (5)) total score at Weeks 12 and 28

    Time frame: Weeks 12 and 28

  7. Secondary Outcome7

    Change from baseline in CAT(COPD Assessment Test,Extremely happy □ 0 □ 1. □ 2, □ 3, □ 4, □ 5 I am extremely unhappy) score at Weeks 4, 8, 12, 16, 20, 24, 28, and 32

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  8. Secondary Outcome8

    Change from baseline in E-RS (Evaluating Respiratory Symptoms,0 points: Not at all;1 point: Slightly;2 points: Moderate;3 points: Serious;4 points: Extremely)score at Weeks 4, 8, 12, 16, 20, 24, 28, and 32

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  9. Secondary Outcome9

    Annualized rate of moderate to severe COPD exacerbations during the 28-week treatment period

    Time frame: Week 28

  10. Secondary Outcome10

    Annualized rate of severe COPD exacerbations during the 28-week treatment period

    Time frame: Week 28

  11. Secondary Outcome11

    Time to first moderate to severe COPD exacerbation during the 28-week treatment period

    Time frame: Week 28

  12. Secondary Outcome12

    Time to first severe COPD exacerbation requiring an emergency room visit or hospitalisation during the 28-week treatment period

    Time frame: Week 28

  13. Secondary Outcome13

    Immunogenicity: Proportion of trial participants positive for ADA and NAb to XKH001 (NAb will be tested if ADA is positive)

    Time frame: Week 36

  14. Secondary Outcome14

    E-R endpoint: Analysis of the relationship between drug exposure and clinical efficacy \[e.g., change from baseline in post-bronchodilator FEV1 (mL) at Week 28\] based on a PopPK model

    Time frame: Week 36

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 20 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 9, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519499
Lead sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

Ting Yang
Contact
dryangting@qq.com
13651380809
Ting Yang
study chair · China-Japan Friendship Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XKH001

Start the discussion